[SCHEDULE 13G] Amedisys Inc SEC Filing

Rhea-AI Filing Summary

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of 1,769,479.30 shares of Amedisys common stock, representing 5.4% of the class. The cover information shows shared voting power of 1,769,412.30 and shared dispositive power of 1,769,477.30, with no sole voting or dispositive power listed.

The filers include a joint filing agreement and certify the securities are held in the ordinary course of business and were not acquired to change or influence control. Reporting classifications include HC, CO, BD, OO, IA, reflecting parent-company and broker/adviser roles.

Positive

• Disclosure of material position: Reporting of 1,769,479.30 shares (5.4%) provides clear, investor-relevant transparency
• Joint filing and certification: Attached joint filing agreement and Item 10 certification clarify ownership structure and ordinary-course intent

Negative

• None.

Insights

Financial Analyst

TL;DR: Goldman Sachs disclosed a material >5% stake (1.77M shares) in Amedisys via a joint Schedule 13G.

The Schedule 13G shows a significant passive holding that meets the SEC's reporting threshold for institutional investors. The filing specifies aggregated beneficial ownership of 1,769,479.30 shares, equal to 5.4% of the class, and reports shared voting and dispositive power rather than sole control. The Item 10 certification and the joint filing agreement increase transparency about intent and ownership structure. For investors, the disclosure signals a notable institutional position without an expressed intent to change corporate control.

Corporate Governance Expert

TL;DR: Shared voting/dispositive power held through a broker/adviser subsidiary is disclosed; joint filing clarifies group relationship.

The filing identifies Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc. and attributes shared voting power of 1,769,412.30 and shared dispositive power of 1,769,477.30. Exhibit information describes the parent-subsidiary relationship and a joint filing agreement, which formalizes the combined disclosure. The Schedule 13G format and the Item 10 certification indicate the holding is presented as ordinary-course, passive ownership rather than an activist stake, while the >5% ownership level is material for governance monitoring and regulatory disclosure obligations.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AMEDISYS, INC.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

023436108

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 023436108

1

Names of Reporting Persons

THE GOLDMAN SACHS GROUP, INC.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,769,412.30
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,769,477.30

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,769,479.30

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 023436108

1

Names of Reporting Persons

GOLDMAN SACHS & CO. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,769,412.30
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,769,477.30

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,769,479.30

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

BD, OO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AMEDISYS, INC.
(b)	Address of issuer's principal executive offices: 3854 AMERICAN WAY, SUITE A, BATON ROUGE, X1, 70816
Item 2.
(a)	Name of person filing: THE GOLDMAN SACHS GROUP, INC.| GOLDMAN SACHS & CO. LLC
(b)	Address or principal business office or, if none, residence: The Goldman Sachs Group, Inc. 200 West Street New York, NY 10282| Goldman Sachs & Co. LLC 200 West Street New York, NY 10282
(c)	Citizenship: THE GOLDMAN SACHS GROUP, INC. - Delaware| GOLDMAN SACHS & CO. LLC - New York
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 023436108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: See the response(s)to Item 11 on the attached cover page(s).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit (99.2)
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

THE GOLDMAN SACHS GROUP, INC.

Signature:	Name: AMEEN SOETAN
Name/Title:	Attorney-in-fact
Date:	07/17/2025

GOLDMAN SACHS & CO. LLC

Signature:	Name: AMEEN SOETAN
Name/Title:	Attorney-in-fact
Date:	07/17/2025

Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of AMEDISYS, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 07/17/2025 THE GOLDMAN SACHS GROUP, INC. By:/s/ AMEEN SOETAN ---------------------------------------- Name: AMEEN SOETAN Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ AMEEN SOETAN ---------------------------------------- Name: AMEEN SOETAN Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group.

FAQ

How many Amedisys (AMED) shares does Goldman Sachs report owning?

The filing reports 1,769,479.30 shares, representing 5.4% of Amedisys common stock.

Which entities filed the Schedule 13G for AMED?

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC are the reporting persons named in the statement.

Does the filing show voting or dispositive power over the shares?

Yes; the filing lists shared voting power of 1,769,412.30 and shared dispositive power of 1,769,477.30, with 0 sole voting or dispositive power.

Is this a joint filing for AMED?

Yes. A joint filing agreement is attached as Exhibit 99.1, and parties authorize joint filing and amendments.

Does the filing indicate intent to influence control of Amedisys?

No; Item 10 certifies the securities are held in the ordinary course of business and were not acquired to change or influence control.